Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference
Genelux: An Oncolytic Virus Player About To Cross The Phase 3 Finish Line, But On Shaky Ground [Seeking Alpha]
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates [Yahoo! Finance]
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates
Genelux (NASDAQ:GNLX) was given a new $20.00 price target on by analysts at Maxim Group.